Head to Head

ASND vs INDV: which is the better buy in 2026?

Ascendis Pharma A/S

NASDAQ:ASND

90/100 Compass
True NorthAccumulate$16.3B

Two rare-disease franchises ramping fast, a TransCon platform with optionality the market still treats as a one-product story.

Full ASND analysis

Indivior Pharmaceuticals, Inc.

NASDAQ:INDV

90/100 Compass
True NorthAccumulate$4.6B

Sublocade is becoming the standard of care for opioid addiction, and Indivior is finally being run like the franchise it owns.

Full INDV analysis

Factor by factor

FactorASNDINDV
Revenue Growth3535
Profitability6646
Valuation8084
Momentum6476
Theme Purity5558
Moat5350
Catalysts6063
Market Position4848

Get head-to-heads like this, free

Join the Alexandria e-letter for Compass verdicts, earnings intelligence, and the contrarian calls the crowd misses. Twice a week, no noise.

Free forever. Unsubscribe anytime. We never share your email.

Frequently asked questions

Is ASND or INDV the better buy in 2026?

ASND and INDV are neck and neck at 90/100 on the Compass right now. The better fit depends on which factors matter most to you.

How does Alexandria compare ASND and INDV?

Each company is scored 1-100 on eight factors: revenue growth, profitability, valuation, momentum, theme purity, moat, catalysts, and market position. The Compass Score is the composite, and the comparison below shows where each name wins factor by factor.

Compass Scores are proprietary editorial research from publicly available data, not investment advice or a recommendation regarding any security. Rankings update weekly.